Integral Health Asset Management’s Viking Therapeutics VKTX Stock Holding History

Integral Health Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200,000	Closed	-$5.3M	–	89
2025 Q2	$5.3M	Hold	200,000	–	–	0.49%	53
2025 Q1	$4.83M	Buy	+200,000	New	+$6.32M	0.51%	53
2024 Q4	–	Sell	-250,000	Closed	-$15.8M	–	100
2024 Q3	$15.8M	Hold	250,000	–	–	1.78%	17
2024 Q2	$13.3M	Buy	+250,000	New	+$16.4M	1.26%	26

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Integral Health Asset Management's VKTX Position: Q1 2026 in Review

Integral Health Asset Management increased its Viking Therapeutics (VKTX) stake by 150% in Q1 2026, buying an estimated $4.82M and bringing the position to 250,000 shares worth $8.13M. The position accounts for 0.39% of the portfolio, ranked #68.

Integral Health Asset Management first reported a position in VKTX in Q4 2022 and has held it in 10 quarters since. The position peaked at $36.9M in Q1 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Integral Health Asset Management held 250,000 shares of Viking Therapeutics worth $8.13M as of Q1 2026.
Integral Health Asset Management bought 150,000 Viking Therapeutics shares in Q1 2026, an estimated $4.82M.
Viking Therapeutics made up 0.39% of Integral Health Asset Management's portfolio in Q1 2026, its #68 holding.
Integral Health Asset Management first reported a position in Viking Therapeutics in Q4 2022 and has held it in 10 quarters since.
Integral Health Asset Management's Viking Therapeutics position peaked at $36.9M in Q1 2024.
412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.